KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

Samankaltaisia teoksia

• Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
  Tekijä: Hodi, F. Stephen, et al.
  Julkaistu: (2013)
• KIT Gene Deletions at the Intron 10−Exon 11 Boundary in GI Stromal Tumors
  Tekijä: Corless, Christopher L., et al.
  Julkaistu: (2004)
• Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
  Tekijä: Serrano, César, et al.
  Julkaistu: (2019)
• Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
  Tekijä: Serrano, César, et al.
  Julkaistu: (2019)
• Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
  Tekijä: Liu, Feiyang, et al.
  Julkaistu: (2019)